IN2015KN00265A - - Google Patents
Info
- Publication number
- IN2015KN00265A IN2015KN00265A IN265KON2015A IN2015KN00265A IN 2015KN00265 A IN2015KN00265 A IN 2015KN00265A IN 265KON2015 A IN265KON2015 A IN 265KON2015A IN 2015KN00265 A IN2015KN00265 A IN 2015KN00265A
- Authority
- IN
- India
- Prior art keywords
- compounds
- hif
- activity
- stability
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
Abstract
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261672191P | 2012-07-16 | 2012-07-16 | |
PCT/US2013/050538 WO2014014834A1 (en) | 2012-07-16 | 2013-07-15 | Process for making isoquinoline compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015KN00265A true IN2015KN00265A (en) | 2015-06-12 |
Family
ID=48857024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN265KON2015 IN2015KN00265A (en) | 2012-07-16 | 2013-07-15 |
Country Status (21)
Country | Link |
---|---|
US (2) | US9340511B2 (en) |
EP (2) | EP2872487B1 (en) |
JP (1) | JP6196671B2 (en) |
KR (1) | KR102145272B1 (en) |
CN (2) | CN106083719B (en) |
AU (1) | AU2013290437B2 (en) |
BR (1) | BR112015001106B1 (en) |
CA (1) | CA2879238C (en) |
DK (1) | DK2872487T3 (en) |
ES (1) | ES2631655T3 (en) |
HU (2) | HUE034409T2 (en) |
IL (1) | IL236625B (en) |
IN (1) | IN2015KN00265A (en) |
MX (1) | MX350922B (en) |
MY (1) | MY171483A (en) |
NZ (1) | NZ704660A (en) |
PL (1) | PL2872487T3 (en) |
PT (1) | PT2872487T (en) |
SG (1) | SG11201500234YA (en) |
WO (1) | WO2014014834A1 (en) |
ZA (1) | ZA201500664B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
EP2872488B1 (en) * | 2012-07-16 | 2018-08-22 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
HUE034409T2 (en) | 2012-07-16 | 2018-02-28 | Fibrogen Inc | Process for making isoquinoline compounds |
EP3708154A1 (en) | 2013-06-06 | 2020-09-16 | Fibrogen, Inc. | Pharmaceutical formulations of a hif hydroxylase inhibitor |
CN103694172A (en) * | 2013-12-26 | 2014-04-02 | 辽宁亿灵科创生物医药科技有限公司 | Derivative of aza-aryl compound |
AU2015311333B2 (en) | 2014-09-02 | 2017-11-16 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
WO2016045125A1 (en) * | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
CN104447547B (en) * | 2014-11-10 | 2017-04-19 | 苏州康润医药有限公司 | Synthesis method of 4-aminoisoquinoline-8-methyl formate |
CN106146490B (en) * | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 5- hydroxyl -1,7- naphthyridine compounds, preparation method and its pharmaceutical applications replaced by aryloxy group or heteroaryloxy |
CN104892509B (en) * | 2015-06-04 | 2018-03-09 | 苏州明锐医药科技有限公司 | Nuo get Si Ta preparation method |
CN106187888A (en) * | 2016-07-18 | 2016-12-07 | 江苏德源药业股份有限公司 | FG 4592 monocrystalline and preparation method thereof |
CN106478503A (en) * | 2016-09-29 | 2017-03-08 | 上海勋和医药科技有限公司 | The preparation method of Roxadustat intermediate |
CZ2016627A3 (en) | 2016-10-07 | 2018-04-18 | Zentiva, K.S. | A method of preparing (7-phenoxy-4-hydroxy-1-methyl-isoquinoline-3-carbonyl)glycine (roxadustate) and its intermediates based on the simultaneous opening of the oxazole ring, ether cleavage and imine formation |
CN107954931B (en) * | 2016-10-17 | 2021-06-22 | 上海医药集团青岛国风药业股份有限公司 | Preparation method of nodispat |
WO2018140186A1 (en) | 2017-01-28 | 2018-08-02 | Kingchem Life Science Llc | A process for preparing 5-phenoxy-1(3h)isobenzofuranone |
JP2021504440A (en) * | 2017-12-01 | 2021-02-15 | ドクター レディズ ラボラトリーズ リミテッド | Method for preparing Lokidustat and its intermediates |
CN109956870A (en) | 2017-12-14 | 2019-07-02 | 南京卡文迪许生物工程技术有限公司 | A kind of Luo Shasi his synthetic method and its midbody compound |
CN110218184B (en) * | 2018-03-01 | 2022-09-27 | 广东东阳光药业有限公司 | Nodesserts eutectic and preparation method thereof |
WO2019174631A1 (en) * | 2018-03-16 | 2019-09-19 | 上海医药集团股份有限公司 | Method for preparing norstat |
CN110526813B (en) * | 2018-05-24 | 2022-06-28 | 杭州科巢生物科技有限公司 | Process for producing isoquinoline compounds and intermediates thereof |
CN112166105B (en) | 2018-06-05 | 2022-03-04 | 沈阳化工大学 | Trifluoroethyl sulfide (sulfoxide) substituted benzene compound and application thereof |
AU2019375983A1 (en) | 2018-11-09 | 2021-06-10 | Vivace Therapeutics, Inc. | Bicyclic compounds |
CN109776415B (en) * | 2019-03-07 | 2020-11-17 | 福建南方制药股份有限公司 | Preparation method of Roxadustat intermediate |
CN114072207B (en) | 2019-04-16 | 2024-03-29 | 维瓦斯治疗公司 | Bicyclic compounds |
RU2709493C1 (en) * | 2019-08-01 | 2019-12-18 | Марат Феликсович Фазылов | Method of producing roxadustat |
EP4010318A1 (en) | 2019-08-07 | 2022-06-15 | Teva Pharmaceuticals International GmbH | Processes for the preparation of roxadustat and intermediates thereof |
CN112441975B (en) * | 2019-09-03 | 2023-10-31 | 西藏嘉信景天药业有限公司 | Preparation method of important intermediate of roflumilast |
CN112679431B (en) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | Method for preparing isoquinolinones compound |
US20230112619A1 (en) * | 2019-10-18 | 2023-04-13 | Shanghai Desano Chemical Pharmaceutical Co., Ltd. | Method for preparing isoquinolinone compounds |
CN112679430B (en) * | 2019-10-18 | 2023-05-05 | 上海迪赛诺化学制药有限公司 | Method for preparing isoquinolinones compound |
CN113444042A (en) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | Preparation method of Rosxastat |
WO2021214785A1 (en) | 2020-04-21 | 2021-10-28 | Mylan Laboratories Limited | Improved process for the preparation of roxadustat |
CN111533691A (en) * | 2020-06-08 | 2020-08-14 | 重庆三圣实业股份有限公司 | Preparation method of Rosxastat |
CN114539149A (en) * | 2020-06-19 | 2022-05-27 | 济川(上海)医学科技有限公司 | Compound containing isoquinoline ring, preparation method and application thereof |
CN112409258A (en) * | 2020-11-20 | 2021-02-26 | 杭州科巢生物科技有限公司 | Preparation method of Rosxastat |
CN114644589A (en) * | 2020-12-17 | 2022-06-21 | 鲁南制药集团股份有限公司 | Preparation method of compound N- [ (4-hydroxy-1-methyl-3-isoquinolyl) carbonyl ] -glycine |
US20230101768A1 (en) * | 2021-08-13 | 2023-03-30 | The Board Of Regents Of The University Of Texas System | Method to treat manganese toxicity and manganese-induced parkinsonism in humans |
CN115124467A (en) * | 2022-07-11 | 2022-09-30 | 天津力生制药股份有限公司 | Preparation method of key intermediate of roxasistat |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
DE2818423A1 (en) | 1978-04-27 | 1979-11-08 | Hoechst Ag | NEW ISOCHINOLINE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
DE3233424A1 (en) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE |
US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
ATE149485T1 (en) | 1993-11-02 | 1997-03-15 | Hoechst Ag | SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS |
ES2101421T3 (en) | 1993-11-02 | 1997-07-01 | Hoechst Ag | SUBSTITUTED HETERO-CYCLIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES. |
TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
WO1996018616A1 (en) | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides |
WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
DE19746287A1 (en) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
FR2779963A1 (en) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis |
IT1302677B1 (en) | 1998-10-15 | 2000-09-29 | Zambon Spa | BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
IT1320162B1 (en) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | DERIVATIVES OF THYROSIN WITH ANTI LEUKOTRIENIC ACTIVITY, PROCEDURES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE. |
FI20002044A0 (en) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Naphthalene derivatives which inhibit Comt enzymes |
DE10110750A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
AU2002241154A1 (en) | 2001-03-21 | 2002-10-03 | Isis Innovation Ltd. | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
US6777425B2 (en) | 2001-06-13 | 2004-08-17 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
AU2002312371A1 (en) | 2001-06-13 | 2002-12-23 | Roland W. Burli | Aryl-benzimidazole compounds having antiinfective activity |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
US8318703B2 (en) | 2001-12-06 | 2012-11-27 | Fibrogen, Inc. | Methods for improving kidney function |
CN100522946C (en) | 2001-12-06 | 2009-08-05 | 法布罗根股份有限公司 | Stabilization of hypoxia inducible factor (HIF) alpha |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7618940B2 (en) * | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
US20060173046A1 (en) | 2003-07-15 | 2006-08-03 | Bell Ian M | Hydroxypyridine cgrp receptor antagonists |
US20070042937A1 (en) | 2003-08-01 | 2007-02-22 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
JP2007501844A (en) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ,インコーポレイテッド | Aryl and heteroaryl compounds, compositions and methods of use |
AU2005250412B2 (en) | 2004-05-28 | 2009-09-17 | Fibrogen, Inc. | HIF prolyl hydroxylase activity assay |
AP2007004047A0 (en) * | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
CN101849943A (en) | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | Use the improved treatment for anemia of HIF alpha stabilizers |
MX2007016160A (en) | 2005-06-15 | 2008-03-07 | Fibrogen Inc | Use of hif 1alfa modulators for treatment of cancer. |
CA2837984C (en) * | 2005-11-28 | 2021-11-16 | Commvault Systems, Inc. | Systems and methods for classifying and transferring information in a storage network |
EP2044028B1 (en) | 2006-01-27 | 2012-05-16 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
AU2007218051A1 (en) | 2006-02-16 | 2007-08-30 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
WO2007115315A2 (en) | 2006-04-04 | 2007-10-11 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
CN103429239A (en) | 2011-01-13 | 2013-12-04 | 菲布罗根有限公司 | Methods for increasing reticulocyte hemoglobin content |
WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
KR102029951B1 (en) * | 2011-07-22 | 2019-11-08 | 베이징 베타 파머수티컬 컴퍼니 리미티드 | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
AU2013229922B2 (en) | 2012-03-09 | 2017-09-28 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors |
EP2872488B1 (en) | 2012-07-16 | 2018-08-22 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
HUE034409T2 (en) | 2012-07-16 | 2018-02-28 | Fibrogen Inc | Process for making isoquinoline compounds |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
AU2014209319B2 (en) | 2013-01-24 | 2018-04-19 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
EP3708154A1 (en) | 2013-06-06 | 2020-09-16 | Fibrogen, Inc. | Pharmaceutical formulations of a hif hydroxylase inhibitor |
-
2013
- 2013-07-15 HU HUE13740184A patent/HUE034409T2/en unknown
- 2013-07-15 EP EP13740184.0A patent/EP2872487B1/en active Active
- 2013-07-15 KR KR1020157003197A patent/KR102145272B1/en active Protection Beyond IP Right Term
- 2013-07-15 CA CA2879238A patent/CA2879238C/en active Active
- 2013-07-15 IN IN265KON2015 patent/IN2015KN00265A/en unknown
- 2013-07-15 JP JP2015523159A patent/JP6196671B2/en active Active
- 2013-07-15 WO PCT/US2013/050538 patent/WO2014014834A1/en active Application Filing
- 2013-07-15 EP EP17155678.0A patent/EP3219706A1/en not_active Withdrawn
- 2013-07-15 AU AU2013290437A patent/AU2013290437B2/en active Active
- 2013-07-15 CN CN201610421229.1A patent/CN106083719B/en active Active
- 2013-07-15 PT PT137401840T patent/PT2872487T/en unknown
- 2013-07-15 BR BR112015001106-3A patent/BR112015001106B1/en active IP Right Grant
- 2013-07-15 SG SG11201500234YA patent/SG11201500234YA/en unknown
- 2013-07-15 ES ES13740184.0T patent/ES2631655T3/en active Active
- 2013-07-15 DK DK13740184.0T patent/DK2872487T3/en active
- 2013-07-15 MY MYPI2015000128A patent/MY171483A/en unknown
- 2013-07-15 MX MX2015000505A patent/MX350922B/en active IP Right Grant
- 2013-07-15 NZ NZ704660A patent/NZ704660A/en unknown
- 2013-07-15 CN CN201310302822.0A patent/CN103435546B/en active Active
- 2013-07-15 US US14/414,879 patent/US9340511B2/en active Active
- 2013-07-15 PL PL13740184T patent/PL2872487T3/en unknown
-
2015
- 2015-01-11 IL IL236625A patent/IL236625B/en active IP Right Grant
- 2015-01-29 ZA ZA2015/00664A patent/ZA201500664B/en unknown
-
2016
- 2016-03-17 US US15/073,251 patent/US9708269B2/en active Active
-
2022
- 2022-06-16 HU HUS2200030C patent/HUS2200030I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015KN00265A (en) | ||
WO2017064566A3 (en) | Inducible modification of a cell genome | |
MX355428B (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]- acetic acid. | |
WO2014100764A3 (en) | Methods of inhibiting prmt5 | |
MX360499B (en) | Microbial strains, compositions, and methods for increasing available phosphate for plants. | |
PH12015502141A1 (en) | Substituted xanthines and methods of use thereof | |
JO3773B1 (en) | P2x7 modulators | |
MY195343A (en) | A Novel Phtalazinone Derivatives and Manufacturing Process Thereof | |
WO2010056767A8 (en) | Thiochromene derivatives as hif hydroxylase inhibitors | |
AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
MX2020001756A (en) | Benzoquinolone inhibitors of vmat2. | |
CA2902795C (en) | Glycopyrrolate salts | |
EA201590887A1 (en) | COMPOSITION | |
WO2014086982A3 (en) | Stable metal compounds, their compositions and methods of their use | |
IN2015DN02793A (en) | ||
MX347882B (en) | Improved process for preparing (3e,7e)-homofarnesol. | |
NZ706838A (en) | Use of p3 of bacteriophage fusion proteins as amyloid binding agents | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
MX2014006337A (en) | Use of p3 of bacteriophage as amyloid binding agents. | |
MX2012010127A (en) | Derivatives of aminoindanes, their preparation and their application in therapeutics. | |
WO2014097318A3 (en) | Agents for eliminating tumour-initiating cells | |
MX2011013878A (en) | Substituted 4-hydroxypyrimidine-5-carboxamides. | |
MX2015016603A (en) | Corticosteroid compositions. | |
IN2014DN10135A (en) | ||
EA201492280A1 (en) | STABLE PEXIGANANE COMPOSITION |